The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Common pitfalls in the diagnosis and management of ATTR-CM and how to overcome them
Ronald Witteles, MD, Stanford University, Stanford, CA, discusses common pitfalls in the diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM). Dr Witteles highlights the importance of screening at-risk patients and appropriate diagnostic testing using monoclonal protein testing and bone scintigraphy. Dr Witteles also discusses current treatment challenges, evolving approaches to atrial fibrillation management, and the importance of genetic testing. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
